Premium
P2‐189: Longitudinal atrophy rate as a biomarker of disease progression in frontotemporal lobar degeneration
Author(s) -
McNaught Elizabeth,
Rohrer Jonathan D.,
Omar Rohani,
Ahsan Laila,
Rossor Martin N.,
Warren Jason D.,
Fox Nick C.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.1263
Subject(s) - atrophy , frontotemporal lobar degeneration , medicine , biomarker , dementia , frontotemporal dementia , semantic dementia , cardiology , pathology , cohort , disease , biochemistry , chemistry
characterized by severe progressive psychobehavioural abnormalities in the absence of significant aphasia, cognitive-intellectual dysfunction or motor features. The neuropathological features were highly consistent, with small, round, neuronal cytoplasmic inclusions that were immunoreactive for ubiquitin (ub-ir), but negative for tau, -synuclein, intermediate filaments and TDP-43. Cytoplasmic inclusions were most numerous in the neocortex, dentate granule cells and hippocampal pyramidal neurons. Ub-ir neuronal intranuclear inclusions were also present in neocortical and hippocampal neurons and had the unusual appearance of straight, curved, or twisted filaments. Conclusions: We believe that these cases represent a new entity that is clinically and pathologically distinct from all currently recognized subtypes of FTLD. Moreover, the existence of such cases indicates that the designations of “FTLD-U” and “TDP-43 proteinopathy” should not be considered to be synonymous.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom